AbbVie Inc. $ABBV Shares Sold by Lmcg Investments LLC

Lmcg Investments LLC cut its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 136,494 shares of the company’s stock after selling 2,882 shares during the quarter. AbbVie makes up 1.8% of Lmcg Investments LLC’s portfolio, making the stock its 11th largest holding. Lmcg Investments LLC’s holdings in AbbVie were worth $29,686,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the 3rd quarter worth about $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at about $28,000. Imprint Wealth LLC raised its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Westend Capital Management LLC acquired a new position in AbbVie in the 4th quarter worth about $29,000. Finally, IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on ABBV shares. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Wells Fargo & Company set a $260.00 price target on shares of AbbVie in a research note on Monday, June 22nd. Guggenheim reissued a “buy” rating and issued a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Finally, Piper Sandler restated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $256.67.

AbbVie Stock Performance

Shares of ABBV stock opened at $254.71 on Wednesday. AbbVie Inc. has a fifty-two week low of $184.63 and a fifty-two week high of $261.64. The stock’s fifty day moving average is $222.39 and its two-hundred day moving average is $220.69. The firm has a market capitalization of $450.02 billion, a P/E ratio of 125.47, a PEG ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 340.89%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.